CFD Liquidation in Korea: Posco DX, Celltrion Siblings, and Potential Next Targets
This post investigates what might have happened to Posco DX today and Celltrion siblings yesterday, which are suspected of being the victim of CFD...
487 Views
Celltrion Healthcare (091990 KS): Portfolio Enhancement to Drive Business Growth
Celltrion Healthcare is expected to launch Humira biosimilar in US in July 2023. Through portfolio expansion, Celltrion aims to increase target...
360 Views
Korea: What Are Foreign Investors Buying & Selling?
Foreign investors have been buying stock in Korea and hold 32% of the KOSPI market cap and 8.5% of the KOSDAQ market cap. There is a big dispersion...
454 Views
SK Pharmteco Pre-IPO Funding & Impact on SK Inc
SK Pharmteco is seeking valuation of about 5 trillion won which is much higher than its book value of 1.65 trillion won. SK Pharmteco (100% owned...
336 Views
Celltrion Inc (068270 KS): Turning Bullish As Biosimilar Revenue Rebounds & US Launches Imminent
Celltrion reported record-high biosimilar quarterly revenue of KRW400B+ in Q1, leading to double-digit revenue and operating profit growth. The...
254 Views